HIGH TIDE INC (HITI.CA) Stock Fundamental Analysis
TSX-V:HITI - TSX Venture Exchange - CA42981E4013 - Common Stock - Currency: CAD
Taking everything into account, HITI scores 4 out of 10 in our fundamental rating. HITI was compared to 34 industry peers in the Pharmaceuticals industry. While HITI seems to be doing ok healthwise, there are quite some concerns on its profitability. HITI has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year HITI has reported negative net income.
HITI had a positive operating cash flow in the past year.
In the past 5 years HITI always reported negative net income.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of HITI (-1.76%) is better than 72.73% of its industry peers.
Looking at the Return On Equity, with a value of -3.03%, HITI is in the better half of the industry, outperforming 75.76% of the companies in the same industry.
HITI's Return On Invested Capital of 5.58% is amongst the best of the industry. HITI outperforms 87.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.76% | ||
| ROE | -3.03% | ||
| ROIC | 5.58% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Operating Margin value of 2.93%, HITI is doing good in the industry, outperforming 75.76% of the companies in the same industry.
With a Gross Margin value of 27.28%, HITI is not doing good in the industry: 60.61% of the companies in the same industry are doing better.
HITI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.93% | ||
| PM (TTM) | N/A | ||
| GM | 27.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HITI is destroying value.
HITI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HITI has been increased compared to 5 years ago.
HITI has a better debt/assets ratio than last year.
2.2 Solvency
HITI has an Altman-Z score of 3.03. This indicates that HITI is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.03, HITI belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
HITI has a debt to FCF ratio of 2.89. This is a good value and a sign of high solvency as HITI would need 2.89 years to pay back of all of its debts.
HITI has a Debt to FCF ratio of 2.89. This is amongst the best in the industry. HITI outperforms 84.85% of its industry peers.
HITI has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.36, HITI perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 2.89 | ||
| Altman-Z | 3.03 |
ROIC/WACC0.67
WACC8.3%
2.3 Liquidity
HITI has a Current Ratio of 1.40. This is a normal value and indicates that HITI is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.40, HITI perfoms like the industry average, outperforming 42.42% of the companies in the same industry.
A Quick Ratio of 0.92 indicates that HITI may have some problems paying its short term obligations.
HITI has a worse Quick ratio (0.92) than 60.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 0.92 |
3. Growth
3.1 Past
The earnings per share for HITI have decreased by -5.00% in the last year.
Looking at the last year, HITI shows a very negative growth in Revenue. The Revenue has decreased by -13.77% in the last year.
The Revenue has been growing by 75.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-240%
Revenue 1Y (TTM)-13.77%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%8.8%
3.2 Future
The Earnings Per Share is expected to grow by 74.44% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 13.54% on average over the next years. This is quite good.
EPS Next Y233.59%
EPS Next 2Y72.1%
EPS Next 3Y84.97%
EPS Next 5Y74.44%
Revenue Next Year14.76%
Revenue Next 2Y17.06%
Revenue Next 3Y16.29%
Revenue Next 5Y13.54%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 43.96 indicates a quite expensive valuation of HITI.
Based on the Price/Forward Earnings ratio, HITI is valued a bit cheaper than the industry average as 75.76% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.68. HITI is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 43.96 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HITI indicates a rather cheap valuation: HITI is cheaper than 81.82% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HITI indicates a somewhat cheap valuation: HITI is cheaper than 75.76% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.6 | ||
| EV/EBITDA | 7.67 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HITI's earnings are expected to grow with 84.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.1%
EPS Next 3Y84.97%
5. Dividend
5.1 Amount
No dividends for HITI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:HITI (2/21/2025, 7:00:00 PM)
3.7
+0.04 (+1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.23%
Inst Owner ChangeN/A
Ins Owners8.82%
Ins Owner ChangeN/A
Market Cap299.33M
Analysts80
Price Target6.97 (88.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-88.08%
Min EPS beat(2)-315.76%
Max EPS beat(2)139.6%
EPS beat(4)3
Avg EPS beat(4)2.25%
Min EPS beat(4)-315.76%
Max EPS beat(4)139.6%
EPS beat(8)7
Avg EPS beat(8)43.06%
EPS beat(12)10
Avg EPS beat(12)24.03%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.53%
Min Revenue beat(2)1.15%
Max Revenue beat(2)1.9%
Revenue beat(4)2
Avg Revenue beat(4)-0.29%
Min Revenue beat(4)-3.51%
Max Revenue beat(4)1.9%
Revenue beat(8)6
Avg Revenue beat(8)1.18%
Revenue beat(12)10
Avg Revenue beat(12)9.7%
Revenue beat(16)13
Avg Revenue beat(16)7.54%
PT rev (1m)11.56%
PT rev (3m)11.56%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)78.55%
EPS NY rev (3m)78.55%
Revenue NQ rev (1m)-1.21%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.64%
Revenue NY rev (3m)1.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 43.96 | ||
| P/S | 0.57 | ||
| P/FCF | 11.6 | ||
| P/OCF | 8.42 | ||
| P/B | 2.09 | ||
| P/tB | 5.93 | ||
| EV/EBITDA | 7.67 |
EPS(TTM)-0.06
EYN/A
EPS(NY)0.08
Fwd EY2.27%
FCF(TTM)0.32
FCFY8.62%
OCF(TTM)0.44
OCFY11.88%
SpS6.46
BVpS1.77
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.76% | ||
| ROE | -3.03% | ||
| ROCE | 8.29% | ||
| ROIC | 5.58% | ||
| ROICexc | 7.37% | ||
| ROICexgc | 19.41% | ||
| OM | 2.93% | ||
| PM (TTM) | N/A | ||
| GM | 27.28% | ||
| FCFM | 4.94% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score6
Asset Turnover2.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 2.89 | ||
| Debt/EBITDA | 1.27 | ||
| Cap/Depr | 38.4% | ||
| Cap/Sales | 1.87% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.32% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z | 3.03 |
F-Score6
WACC8.3%
ROIC/WACC0.67
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-240%
EPS Next Y233.59%
EPS Next 2Y72.1%
EPS Next 3Y84.97%
EPS Next 5Y74.44%
Revenue 1Y (TTM)-13.77%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%8.8%
Revenue Next Year14.76%
Revenue Next 2Y17.06%
Revenue Next 3Y16.29%
Revenue Next 5Y13.54%
EBIT growth 1Y372.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year489.9%
EBIT Next 3Y135.82%
EBIT Next 5Y83.86%
FCF growth 1Y76.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.04%
OCF growth 3YN/A
OCF growth 5YN/A